Lok positive non-small cell lung cancer with diagnosis approved today

Source: Wuxi apptec 2017-06-02 today, Roche announced that the FDA of the United States has approved Ventana ALK (d5f3) CDX test kit as a concomitant diagnosis for the identification of ALK positive non-small cell lung cancer (NSCLC) patients to determine whether it is suitable for the use of Novartis drug product zykadia (ceritinib) At present, Ventana ALK (d5f3) assay is the only one approved by FDA as an IHC assay for zykadia concomitant diagnosis ▲ ALK positive non-small cell lung cancer accompanied by the diagnosis process (photo source: Ventana ALK official website) Roche is one of the global pioneers in medicine and diagnostics, focusing on promoting science to improve people's quality of life The comprehensive advantages of integrating drug treatment and reasonable diagnosis under the same roof make Roche one of the leading enterprises in the field of individualized health care This strategy aims to provide correct treatment for each patient in the best way ▲ lung cancer in non-small cell lung cancer tissues (photo source: Ventana ALK official website) detected and amplified with Ventana ALK (d5f3) CDX and OptiView DAB is still one of the main causes of cancer death Each year, more than 1.6 million people die of the disease worldwide The purpose of Ventana ALK (d5f3) CDX assay was to detect the protein of anaplastic lymphoma kinase (ALK) in formalin fixed paraffin embedded (FFPE) non-small cell lung cancer (NSCLC) tissues The samples were stained by benchmark XT or benchmark ultra automatic staining instrument ALK anaplastic lymphoma kinase is an important biomarker in non-small cell lung cancer, and its detection and inhibition can help shrink the tumor size of some ALK positive patients; this identification result helps to determine patients who meet the treatment conditions of xalkori (crizotinib) or zykadia (ceritinib) The results of this product should be interpreted by a qualified pathologist in combination with histological examination, relevant clinical information and appropriate reference information This product is used for in vitro diagnosis (IVD) Dr Ann Costello, head of Roche tissue diagnostics, commented: "FDA approved the expanded use of Ventana ALK (d5f3) CDX assay to determine which lung cancer patients meet the zykadia standard We are helping clinicians and their patients identify alternative treatments for NSCLC, another good example of Roche's continued commitment to advancing standards of care and individualized medicine for lung cancer patients "